Paces Ferry Wealth Advisors LLC Invests $232,000 in Insulet Co. (NASDAQ:PODD)

Paces Ferry Wealth Advisors LLC bought a new position in Insulet Co. (NASDAQ:PODD) in the 4th quarter, Holdings Channel.com reports. The fund bought 1,068 shares of the medical instruments supplier’s stock, valued at approximately $232,000.

Several other large investors also recently made changes to their positions in the stock. Parkside Financial Bank & Trust increased its stake in shares of Insulet by 251.0% in the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 123 shares during the period. Allworth Financial LP increased its position in Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 92 shares during the period. Wolff Wiese Magana LLC raised its stake in Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares during the last quarter. BluePath Capital Management LLC bought a new stake in Insulet in the 3rd quarter valued at $31,000. Finally, Lindbrook Capital LLC grew its position in Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently commented on PODD. Piper Sandler cut their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Stifel Nicolaus upped their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Barclays reduced their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. boosted their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $243.21.

Insider Buying and Selling

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Insulet Price Performance

Shares of NASDAQ:PODD traded up $1.68 during trading on Tuesday, reaching $171.94. The stock had a trading volume of 758,586 shares, compared to its average volume of 857,969. The stock has a market capitalization of $12.04 billion, a PE ratio of 59.09, a P/E/G ratio of 2.99 and a beta of 0.98. Insulet Co. has a 52 week low of $125.82 and a 52 week high of $335.91. The business’s 50-day moving average price is $171.09 and its 200 day moving average price is $180.25. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. As a group, equities analysts predict that Insulet Co. will post 3.08 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.